Want to see HK:1228 full AI Analyst Report?
1228 Stock Chart & Stats
HK$2.52
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.52
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$1.61 - HK$3.50
Previous CloseN/A
Volume661.00K
Average Volume (3M)964.62K
Market Cap
HK$1.23B
Enterprise ValueHK$1.45B
Total Cash (Recent Filing)HK$88.10M
Total Debt (Recent Filing)HK$28.81M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding597,723,300
10 Day Avg. Volume1,348,112
30 Day Avg. Volume964,617
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)-3.07
Price to Sales (P/S)21.02
P/FCF Ratio-27.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
Bulls Say, Bears Say
Bulls Say
Debt ReductionDebt fell significantly by 2025 versus 2024, reducing near-term leverage pressure and showing some balance-sheet de-risking. This may preserve funding flexibility over the next several quarters, although negative equity means the improvement does not remove broader capital-structure fragility.
Improved Net IncomeThe sharp improvement in 2025 net income indicates progress relative to prior loss levels and could support investor confidence if repeated. However, the benefit is not yet clearly durable because operating profitability remains deeply negative and current revenue has contracted.
Gross Margin StrengthRelatively strong gross margins provide a constructive base for the rare-disease commercial model, retaining meaningful revenue after direct costs. If revenue scales, this margin profile could help operating leverage emerge, though current EBIT losses show that overhead still exceeds gross profit.
Bears Say
Negative Shareholders' EquityPersistent negative shareholders’ equity signals a fragile capital structure and limits financial flexibility over the medium term. It also makes leverage metrics harder to interpret and increases the company’s exposure to financing pressure while it continues developing and commercializing its therapies.
Ongoing Cash BurnRecurring negative operating and free cash flow shows that the business has not yet demonstrated sustained self-funding capacity. Even though the magnitude of cash burn improved in 2025, continued funding needs can constrain investment choices and raise financing or dilution risk.
Contracting Revenue And Deep EBIT LossesRecent revenue contraction weakens evidence of commercial scale and makes it harder for the company to absorb its cost base. Deeply negative EBIT across the period indicates that improved net income has not translated into operating profitability, limiting confidence in earnings durability.
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$1.61 and its highest was HK$3.50 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.23B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Apr 01, 2027 which is in 178 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.075 earnings per share for the quarter.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 597,723,300 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of -HK$0.075 in its last earnings report. Following the earnings report the stock price went down -3.713%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―